keyword
MENU ▼
Read by QxMD icon Read
search

paliperidone

keyword
https://www.readbyqxmd.com/read/28809128/real-world-adherence-and-economic-outcomes-associated-with-paliperidone-palmitate-versus-oral-atypical-antipsychotics-in-schizophrenia-patients-with-substance-related-disorders-using-medicaid-benefits
#1
Kruti Joshi, Marie-Hélène Lafeuille, Rhiannon Kamstra, Sean Tiggelaar, Patrick Lefebvre, Edward Kim, Yong Yue, Neeta Tandon
AIM: Compare medication utilization, costs and healthcare resource use in schizophrenia patients with substance-related disorders initiated on once-monthly paliperidone palmitate (PP1M) or an oral atypical antipsychotic (OAA). MATERIALS & METHODS: Data from six Medicaid states (07/2009-03/2015) were used to compare outcomes between PP1M and OAA patients. RESULTS: PP1M patients had higher 12-month antipsychotic adherence and persistence than OAA patients...
August 15, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28806194/paliperidone-palmitate-3-month-treatment-results-in-symptomatic-remission-in-patients-with-schizophrenia-a-randomized-multicenter-double-blind-and-noninferiority-study
#2
Adam J Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, David Hough, Maju Mathews
The current analysis assessed symptomatic and functional remission achieved following paliperidone palmitate 3-month (PP3M) versus 1-month (PP1M) treatment in patients (age: 18-70 years) with schizophrenia, previously stabilized on PP1M. Following a less than or equal to 3-week screening, and a 17-week, flexible-dosed, open-label phase [PP1M: day 1 (150 mg eq. deltoid), day 8 (100 mg eq. deltoid), weeks 5, 9, and 13 (50, 75, 100, or 150 mg eq., deltoid/gluteal)], clinically-stable patients were randomized (1 : 1) to PP3M (fixed-dose, 175, 263, 350, or 525 mg eq...
August 11, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28797721/intact-blood-brain-barrier-transport-of-small-molecular-drugs-in-animal-models-of-amyloid-beta-and-alpha-synuclein-pathology
#3
Sofia Gustafsson, Veronica Lindström, Martin Ingelsson, Margareta Hammarlund-Udenaes, Stina Syvänen
Pathophysiological impairment of the neurovascular unit, including the integrity and dynamics of the blood-brain barrier (BBB), has been denoted both a cause and consequence of neurodegenerative diseases. Pathological impact on BBB drug delivery has also been debated. The aim of the present study was to investigate BBB drug transport, by determining the unbound brain-to-plasma concentration ratio (Kp,uu,brain), in aged AβPP-transgenic mice, α-synuclein transgenic mice, and wild type mice. Mice were dosed with a cassette of five compounds, including digoxin, levofloxacin (1 mg/kg, s...
August 5, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28783941/five-month-persistent-extrapyramidal-symptoms-following-a-single-injection-of-paliperidone-palmitate-a-case-report
#4
Seoyoung Jang, Jungmin Woo
Long-acting injectable (LAI) antipsychotics are useful in the treatments for schizophrenic patients with poor adherence due to their maintaining feature of therapeutic plasma level without daily administrations. However, their long-lasting property can cause complicated problems such as a long-lasting side effect. We report a patient who experienced LAI-induced extrapyramidal symptoms (EPSs) for 5 months after a single injection. During that period, every trial to ameliorate this condition turned out to be a failure...
August 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28762843/cost-effectiveness-of-3-month-paliperidone-therapy-for-chronic-schizophrenia-in-the-netherlands
#5
Thomas R Einarson, Basil G Bereza, Fadi Tedouri, Kristel Van Impe, Tom R Denee, Pieter J T Dries
BACKGROUND: A new depot formulation of paliperidone has been developed that provides effective treatment for schizophrenia for three months (PP3M). It has been tested in phase-3 trials, but no data on its cost-effectiveness have been published. PURPOSE: To determine the cost-effectiveness of PP3M compared with once-monthly paliperidone (PP1M), haloperidol long-acting therapy (HAL-LAT), risperidone microspheres (RIS-LAT), and oral olanzapine (oral-OLZ) for treating chronic schizophrenia in The Netherlands...
August 1, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28751663/caregiver-burden-in-schizophrenia-following-paliperidone-palmitate-long-acting-injectables-treatment-pooled-analysis-of-two-double-blind-randomized-phase-three-studies
#6
Srihari Gopal, Haiyan Xu, Kelly McQuarrie, Adam Savitz, Isaac Nuamah, Kimberly Woodruff, Maju Mathews
The pooled analysis of two double-blind, randomized, multicenter, phase-3 studies evaluated predictors of improvement or worsening of schizophrenia-related caregiver burden following paliperidone palmitate long-acting injectables (1-monthly [PP1M] and 3-monthly [PP3M]) treatment. Caregivers were offered to complete the involvement evaluation questionnaire (involvement evaluation questionnaire; 31-item scale). Total, 1498 caregivers (intent-to-treat open-label analysis set, n = 1497; mean [SD] age: 51.5 [13...
July 27, 2017: NPJ Schizophrenia
https://www.readbyqxmd.com/read/28748368/development-and-evaluation-of-ph-responsive-cyclodextrin-based-in-situ-gel-of-paliperidone-for-intranasal-delivery
#7
Atul P Sherje, Vaishali Londhe
Paliperidone (PLPD) is approved for treatment and management of schizophrenia. The current study demonstrates the potential of in situ gel of PLPD for nasal delivery. The permeation of drug through sheep nasal mucosa was analyzed since the nose-to-brain pathway has been indicated for delivering drugs to the brain. The carbopol 934 (CP)- and hydroxypropyl methyl cellulose K4M (HPMC)-based in situ gels containing 0.2% CP and 0.4% w/v HPMC were optimized using experimental design software. The use of hydroxypropyl-β-cyclodextrin (HP-β-CD) in nasal permeation of drug was investigated...
July 26, 2017: AAPS PharmSciTech
https://www.readbyqxmd.com/read/28741387/baseline-characteristics-and-treatment-patterns-of-patients-with-schizophrenia-initiated-on-once-every-three-month-paliperidone-palmitate-in-the-real-world-setting
#8
Kruti Joshi, Marie-Hélène Lafeuille, Brianne Brown, Willy Wynant, Bruno Emond, Patrick Lefebvre, Neeta Tandon
OBJECTIVES: Since May 2015, adult patients with schizophrenia adequately treated with once-monthly paliperidone palmitate (PP1M) may be transitioned to once-every-three-month paliperidone palmitate (PP3M). This study aims to describe baseline characteristics and treatment patterns of patients with schizophrenia initiated on PP3M in the real-world setting. METHODS: Pharmacy and medical claims from 05/2014-09/2016 for adult patients with schizophrenia initiated on PP3M (index date) in the Symphony Health Solutions database were analyzed...
July 25, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28738100/multiple-neurotoxic-effects-of-haloperidol-resulting-in-neuronal-death
#9
Henry A Nasrallah, Alexander T Chen
BACKGROUND: Several published studies have reported an association between antipsychotic medications, especially first-generation agents, and a decline in gray matter volume. This prompted us to review the possible neurotoxic mechanisms of first-generation antipsychotics (FGAs), especially haloperidol, which has been widely used over the past several decades. METHODS: A PubMed search was conducted using the keywords haloperidol, antipsychotic, neurotoxicity, apoptosis, oxidative stress, and neuroplasticity...
August 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28735640/dose-equivalents-for-second-generation-long-acting-injectable-antipsychotics-the-minimum-effective-dose-method
#10
REVIEW
Philipp H Rothe, Stephan Heres, Stefan Leucht
BACKGROUND: The concept of dose equivalence of depot medication is important for many scientific and clinical purposes. METHODS: A systematic literature search on four second-generation antipsychotics available as long-acting injectable drugs and haloperidol was conducted. We used the minimum effective dose method which is based on randomized fixed dose studies where the smallest dose which was significantly more efficacious than placebo in the primary outcome was declared as minimum effective dose...
July 21, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28721057/safety-tolerability-and-risks-associated-with-first-and-second-generation-antipsychotics-a-state-of-the-art-clinical-review
#11
REVIEW
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll, André F Carvalho
Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients - psychosocial functioning, quality of life, and recovery...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28712616/aripiprazole-lauroxil-compared-with-paliperidone-palmitate-in-patients-with-schizophrenia-an-indirect-treatment-comparison
#12
REVIEW
Chris Cameron, Jacqueline Zummo, Dharmik N Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for treatment of schizophrenia on the basis of a large-scale trial of two doses of AL versus placebo. There are no direct-comparison studies with paliperidone palmitate (PP; long-acting antipsychotic used most often in acute settings) for the acute psychotic episode. OBJECTIVES: To indirectly compare efficacy and safety of the pivotal AL study with all PP studies meeting indirect comparison criteria...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28706556/corrigendum-pharmacoeconomic-comparison-of-aripiprazole-once-monthly-and-paliperidone-palmitate-from-a-head-to-head-clinical-trial-in-schizophrenia-a-us-analysis
#13
(no author information available yet)
[This corrects the article on p. 212301 in vol. 5, PMID: 27708677.].
2017: Drugs in Context
https://www.readbyqxmd.com/read/28678566/cost-effectiveness-of-3-month-paliperidone-treatment-for-chronic-schizophrenia-in-spain
#14
Thomas R Einarson, Basil G Bereza, Ignacio Garcia Llinares, Beatriz González Martín Moro, Fadi Tedouri, Kristel Van Impe
BACKGROUND: A three-month long treatment of paliperidone palmitate (PP3M) has been introduced as an option for treating schizophrenia. Its cost-effectiveness in Spain has not been established. AIMS: To compare the costs and effects of PP3M compared with once-monthly paliperidone (PP1M) from the payer perspective in Spain. METHODS: We used the recently published trial by Savitz (2016) as a core model over one year. Additional data were derived from the literature...
July 5, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28675307/pharmacokinetic-drug-evaluation-of-paliperidone-in-the-treatment-of-schizoaffective-disorder
#15
REVIEW
Matthew Macaluso, Hannah Oliver, Zohaib Sohail
This paper reviews the pharmacokinetics, receptor binding, clinical efficacy and safety of paliperidone in the treatment of patients with schizoaffective disorder. Areas covered: We reviewed the literature using keywords 'paliperidone', 'schizoaffective disorder' and 'clinical trials' with a focus on seminal data papers and information that is clinically relevant to the treatment of schizoaffective disorder. The purpose of this paper is to provide a clinically oriented review of the pharmacokinetic and pharmacodynamic properties of paliperidone including receptor binding, clinical efficacy, safety and tolerability...
August 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28672735/safety-concerns-associated-with-second-generation-antipsychotic-long-acting-injection-treatment-a-systematic-update
#16
Salvatore Gentile
Background It has been recently suggested that second-generation antipsychotic long-acting injection (SGA-LAIs) are underutilized in clinical practice, despite that their costs significantly impact on national health system budgets. Hence, an updated analysis of safety data shown by SGA-LAIs may contribute to clarify their role in clinical practice. Materials and methods English-language, peer-reviewed articles reporting updated, primary findings on the SGA-LAI safety were identified (updated through an electronic search of five databases - PubMed, EMBASE, PsycInfo, DARE and the Cochrane Library)...
June 23, 2017: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/28660406/evaluation-of-potentially-prolactin-related-adverse-events-and-sexual-maturation-in-adolescents-with-schizophrenia-treated-with-paliperidone-extended-release-er-for-2-years-a-post-hoc-analysis-of-an-open-label-multicenter-study
#17
Srihari Gopal, Rosanne Lane, Isaac Nuamah, Margaret Copenhaver, Jaskaran Singh, David Hough, Mark Bach, Adam Savitz
BACKGROUND: Elevated prolactin levels (hyperprolactinemia) are a frequent adverse effect of antipsychotic medications, especially in young populations. Prolonged hyperprolactinemia may affect sexual functioning and the onset and progression of puberty. OBJECTIVE: This study assessed potentially prolactin-related treatment-emergent adverse events (PPRL-TEAEs) and sexual maturation during long-term treatment of adolescents with paliperidone extended-release (ER). METHODS: This post hoc analysis of a 2-year open-label multicenter study (NCT00488319) included patients of either sex aged 12-17 years at study enrollment, diagnosed with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, 4th edition [DSM-IV]) for ≥1 year, who had received one or more adequate antipsychotic treatment prior to enrollment but had not responded sufficiently...
June 28, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28647739/antipsychotic-induced-dopamine-supersensitivity-psychosis-pharmacology-criteria-and-therapy
#18
Guy Chouinard, Anne-Noël Samaha, Virginie-Anne Chouinard, Charles-Siegfried Peretti, Nobuhisa Kanahara, Masayuki Takase, Masaomi Iyo
The first-line treatment for psychotic disorders remains antipsychotic drugs with receptor antagonist properties at D2-like dopamine receptors. However, long-term administration of antipsychotics can upregulate D2 receptors and produce receptor supersensitivity manifested by behavioral supersensitivity to dopamine stimulation in animals, and movement disorders and supersensitivity psychosis (SP) in patients. Antipsychotic-induced SP was first described as the emergence of psychotic symptoms with tardive dyskinesia (TD) and a fall in prolactin levels following drug discontinuation...
2017: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/28645134/-arterial-hyper-and-hypotension-associated-with-psychiatric-medications-a-risk-assessment-based-on-the-summaries-of-product-characteristics-smpcs
#19
Roland W Freudenmann, Ninja Freudenmann, Bartosz Zurowski, Carlos Schönfeldt-Lecuona, Ludwig Maier, Roland E Schmieder, Christian Lange-Asschenfeldt, Maximilian Gahr
Introduction Psychiatric medications are well-known triggers of clinically relevant blood pressure changes. Therefore, we aimed at creating ranking lists for their risk of causing arterial hyper- or hypotension. Methods We analyzed 784 Summaries of Product characteristics (SmPCs, available online from "Rote Liste" or "Gelbe Liste" websites) from 105 psychiatric medications registered in adult psychiatry in Germany and extracted the standardized reported risks of increasing or decreasing arterial blood pressure...
August 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28641996/impact-of-paliperidone-palmitate-versus-oral-atypical-antipsychotics-on-health-care-resource-use-and-costs-in-veterans-with-schizophrenia-and-comorbid-substance-abuse
#20
Patrick Lefebvre, Erik Muser, Kruti Joshi, Maral DerSarkissian, Rachel H Bhak, Mei Sheng Duh, Brian Shiner, Yinong Young-Xu
PURPOSE: Almost half of all patients diagnosed with schizophrenia have a history of substance abuse (SA). However, data on treatment of schizophrenia with paliperidone palmitate (PP) among patients with comorbid SA are limited. The objective of this study was to compare all-cause and SA-related health care resource utilization and costs in veterans with schizophrenia and co-occurring SA who were treated with PP versus oral atypical antipsychotics (OAAs). METHODS: Veterans Health Administration electronic health record data were used to conduct a retrospective longitudinal study in veterans with schizophrenia who initiated PP or OAA between January 1, 2010 and June 30, 2016, had ≥12 months of enrollment before treatment initiation (baseline), were diagnosed with SA, and had ≥1 Global Assessment of Functioning score during baseline...
July 2017: Clinical Therapeutics
keyword
keyword
32835
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"